Clofedanol
group of stereoisomers
Clofedanol (INN) or chlophedianol (BAN), sold under the brand name Ninjacof among others, is a centrally acting cough suppressant used in the treatment of dry cough. Clofedanol has local anesthetic, antispasmodic, and antihistamine properties, and may have anticholinergic effects at high doses.
Side effects
Adverse effects may include irritability, drowsiness, nightmares, vertigo, nausea or vomiting, visual disturbances or hallucinations, and urticaria. There are potential interactions with other anticholinergics, CNS depressants, and alcohol.
Pharmacology
Unlike many other antitussive drugs such as dextromethorphan, it binds poorly to the sigma-1 receptor.
Society and culture
Chlophedianol was approved for OTC status in 1987 by the FDA OTC monograph process and its safety and efficacy data are limited. It was formerly sold over-the-counter in the United States under the trade name Ulo, as a syrup with a dosage of 25 mg/5 mL. It is now marketed under the brand name of Ninjacof and others in the U.S.
It is marketed in Canada under the trade name Ulone. GM Pharmaceuticals owns the patents to 113 combinations with Chlophedianol and was the first company to launch the cough suppressant in the United States.
It is sold in Japan as an over-the-counter drug under the name Coldrin. It has been marketed in Germany as Pectolitan and in Spain as Gentos.
Begin with the source’s own compact description: “Clofedanol” is group of stereoisomers. The dossier treats that line as a proposition to test through Clofedanol, group and stereoisomers, not as a finished interpretation.
Why this record matters
The phrase “group of stereoisomers” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Jul 15, 2026. The linked authority identifier is Q2964078. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1987.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Clofedanol”, its source revision and the description used here.
- Expand the search: follow Clofedanol primary sources, Clofedanol archive and Clofedanol research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Clofedanol”?
- What terminology or title could unlock a more precise catalogue search?
- Which cited source is closest to the event, object or claim?
Search terms from this dossier
This entry incorporates text from “Clofedanol” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.